Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$7.76 - $10.29 $1.71 Million - $2.27 Million
220,712 Added 222.58%
319,872 $3.22 Million
Q3 2023

Nov 14, 2023

BUY
$9.14 - $24.62 $906,322 - $2.44 Million
99,160 New
99,160 $929,000
Q1 2023

May 15, 2023

BUY
$22.26 - $30.85 $2.42 Million - $3.35 Million
108,507 New
108,507 $2.52 Million
Q3 2022

Nov 14, 2022

BUY
$18.26 - $31.1 $3.02 Million - $5.15 Million
165,460 New
165,460 $3.19 Million
Q2 2022

Aug 15, 2022

SELL
$19.08 - $26.7 $415,982 - $582,113
-21,802 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$21.19 - $40.01 $461,984 - $872,298
21,802 New
21,802 $561,000
Q4 2021

Feb 14, 2022

SELL
$30.97 - $54.03 $1.73 Million - $3.02 Million
-55,974 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$34.9 - $54.54 $1.95 Million - $3.05 Million
55,974 New
55,974 $2.44 Million

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $1.28B
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Twinbeech Capital LP Portfolio

Follow Twinbeech Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Twinbeech Capital LP with notifications on news.